Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The acquisition ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total price contingent on future development and regulatory milestones beyond the ...

Sanofi to pay $1.15 billion upfront for Vicebio, with up to $450 million in milestone payments. Vicebio’s VXB-241 RSV-hMPV combo vaccine is in Phase 1 trials in older adults. Get the data-driven ...

Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's molecular clamp technology against life-threatening respiratory viruses. Vicebio, ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...